Palliative care 2016

Retrospec+ve cohorts

Author/year

# pts. LNmet/ total

Primary

Fract x dose Local control 2-­‐years

Survival 2-­‐years

Severe morbidity

Kang 2010

26/59

CRC

3 x 12-­‐17Gy

66%

66%

Grade 4 (n=2)

Bignardi 2011

19

Mixed

6 x 7.5Gy

78

NA

Grade 3 (n=1)

Prostate cancer

3 x 9-­‐10Gy; 5 x 7Gy

Petrongari 2011

12/12

3/12

NA

No

64% (3-­‐years)

60% (3-­‐years)

Bae 2012

18/41

CRC

3 x 15-­‐17Gy

Grade>3 (n=3)

Jereczek-­‐Fossa 2012 Favorable local control, but lymph node metastasis pa+ents not reported separately 14/14 3 x 10Gy 14/14 65% No Bercovic 2013 11/24 10 x 5Gy 11/11 NA No

Prostate cancer Prostate cancer

10 x 4-­‐5Gy; 3 x 12Gy; 5 x 8.5Gy 3 x 15Gy (isocenter)

32% (3-­‐years)

De Vin 2014

88/309

Mixed

33%

NR

Fode 2015

6/201 Mixed (CRC)

6/6

58%*

No

Ost 2016

77/119 Prostate

Varying

93%

48%*

No